Overcoming resistance against HER2-targeting agents in fifth-line therapy: is there still a place for bevacizumab in HER2+ breast cancer?

Florian Huemer; Simon Peter Gampenrieder; Alexander Schlattau; Richard Greil

doi:10.1016/j.clbc.2013.09.009

Overcoming resistance against HER2-targeting agents in fifth-line therapy: is there still a place for bevacizumab in HER2+ breast cancer?

Florian Huemer (Erstautor/-in), Simon Peter Gampenrieder (Co-Autor/-in), Alexander Schlattau (Co-Autor/-in), Richard Greil (Letztautor/-in)

Universitätsklinik für Innere Medizin 3 - Hämatologie, internistische Onkologie, Hämostaseologie, Infektiologie, Rheumatologie und Onkologisches Zentrum
Universitätsinstitut für Radiologie

Publikation: Beitrag in Fachzeitschrift › Fallbericht › Begutachtung

Originalsprache	Englisch
Seiten (von - bis)	e17-e20
Fachzeitschrift	CLINICAL BREAST CANCER
Jahrgang	14
Ausgabenummer	1
DOIs	https://doi.org/10.1016/j.clbc.2013.09.009
Publikationsstatus	Veröffentlicht - 2014

Zugriff auf Dokument

10.1016/j.clbc.2013.09.009

Dieses zitieren

@article{b60c81a170af495e933539fbccb3c739,

title = "Overcoming resistance against HER2-targeting agents in fifth-line therapy: is there still a place for bevacizumab in HER2+ breast cancer?",

author = "Florian Huemer and Gampenrieder, {Simon Peter} and Alexander Schlattau and Richard Greil",

note = "1 Third Medical Department with Hematology, Medical Oncology, Hemostaseology, Infectious Diseases and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; 2 Department of Radiology, Paracelsus Medical University Salzburg, Salzburg, Austria",

year = "2014",

doi = "10.1016/j.clbc.2013.09.009",

language = "English",

volume = "14",

pages = "e17--e20",

journal = "CLINICAL BREAST CANCER",

issn = "1526-8209",

number = "1",